Future scope: the next decade.
Each projection is calibrated against working-group charters, draft documents, inspection patterns and conference outputs. Absence of signal means LOW confidence by definition.
Future scope · 2026–2035.
Projections · confidence calibrated to public signalsEach projection is calibrated against working-group charters, draft documents, inspection patterns and conference outputs. Absence of signal means LOW confidence by definition.
Virtual BE as primary evidence.
Selected complex generics by 2030–2035. Realistic 2026–2030: PBPK supportive for BCS biowaivers, food-effect waivers, dose proportionality. 2030–2035: PBPK + reduced in vivo confirmatory hybrid for technical-impossibility cases.
Long-acting injectable BE frameworks.
By 2028–2030. Risperidone microspheres, paliperidone palmitate, naltrexone depot, GLP-1 LAI generics entering 2026+. FDA PSGs expected 2028; EMA reflection 2027–2029. Steady-state designs and IVIVC release-rate surrogates replacing single-dose crossover.
Complex generic frameworks.
Peptides, suspensions, drug-device. FDA glatiramer acetate (2015) set peptide precedent; liraglutide / semaglutide post-patent pressure drives peptide guidance attempts 2027–2030. ICH-level peptide guidance attempt expected with partial convergence only.
Drug-device BE bridge.
Device interchangeability becomes a regulatory question (patient hand-feel of generic inhaler). FDA orally-inhaled guidance under continuing revision. EU MDR Article 117 notified-body bottleneck easing but still ~12-month review vs. 45-day medicinal-product timeline.
Biosimilar interchangeability.
Convergence by 2030. FDA expanding interchangeability grants; EMA likely to publish federal framework 2027–2028 (member-state pushback expected); ANVISA possible introduction 2028–2030. Realistic: totality-of-evidence without mandatory switching for established biosimilars.
ANVISA-ICH biowaiver operationalisation.
2026–2030. 50–100 case-law decisions expected; ANVISA may publish biowaiver-specific operational guidance ~2028. Persistent Brazilian divergences: locally registered reference, volunteer registry, genotoxic impurity records.
HRMS bioanalytical baseline.
By 2028. Orbitrap, Q-TOF, FT-ICR mature. ICH M10 amendment / companion guidance expected 2028–2030. Mass-accuracy criteria (≤5 ppm) and isotope-pattern confirmation standards setting.
Microsampling standard.
DBS, VAMS by 2030. Currently case-by-case under ICH M10. Population studies, paediatrics and decentralised trials driving acceptance.
Genomic-stratified BE.
2030+. Metabolizer-specific BE designs for CYP polymorphism populations; technically feasible but politically and payer-resisted more than regulatorily.
RWE for post-approval BE.
2030+. Real-world evidence as confirmatory substrate. Technically feasible; politically contested; liability questions unresolved.